BioPharma Resources

Drug Trial Radar · NCT06970665

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

A Phase 3/4, Multicenter, Single-arm Clinical Study to Assess the Safety of Intravitreal Administration of ASP3021 in Participants in Japan With Geographic Atrophy Secondary to Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

17

Actual

Start

Jul 8, 2025

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
May 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their vision over time. AMD damages the macula, which is in the middle of the retina - the light sensitive part at the back of the eye. In AMD, the cells in the macula die over time, usually over several years, leading to vision loss. When AMD gets worse, it can turn into either geographic atrophy (GA), neovascular AMD, or both. This study is for people in Japan of 40 years of age or older, who have geographic atrophy. The main aim of this study is to collect information about the safety of ASP3021 and how well people tolerate treatment with ASP3021. During the study, people will receive monthly injections of ASP3021 for 12 months. ASP3021 is given by injection into the affected eye. This procedure is called an intravitreal injection. People will be in the study for about 1 year. People will visit their study clinic several times for health checks.

Conditions

  • Geographic Atrophy
  • Age-Related Macular Degeneration

Interventions

  • avacincaptad pegolDrug

    intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 12 Months
  2. Number of participants with Serious TEAEsTime frame: Up to 12 Months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Fukushima Medical University Hospital

    Fukushima, Fukushima, Japan

  • Kagawa University Hospital

    Kita-gun, Kagawa-ken, Japan

  • Yokohama City University Medical Center

    Yokohama, Kanagawa, Japan

  • Kyoto University Hospital

    Kyoto, Kyoto, Japan

  • Nagasaki University Hospital

    Nagasaki, Nagasaki, Japan

  • University of the Ryukyus hospital

    Ginowan-shi, Okinawa, Japan

  • Kansai Medical University Hospital

    Hirakata-shi, Osaka, Japan

  • The University of Osaka Hospital

    Suita-shi, Osaka, Japan

  • Toyama University Hospital

    Toyama, Toyama, Japan

  • University Of Yamanashi Hospital

    Chuo-shi, Yamanashi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.